Potential Management of Circulating Tumor DNA As a Biomarker in Triple-Negative Breast Cancer

Overview

Journal J Cancer

Specialty Oncology

Date 2018 Dec 28

PMID 30588246

Citations 19

Authors

Mao Shang

Chunxiao Chang

Yanqing Pei

Yin Guan

Jin Chang

Huihui Li

Affiliations

Soon will be listed here.

Abstract

As a specific subtype of breast cancer, Triple-negative breast cancer (TNBC) is associated with worse prognosis and higher tumor aggressiveness than HER2-amplified or hormone receptor positive breast cancers. Circulating tumor DNA (ctDNA), as a non-invasive "liquid biopsy", is an emerging original blood-based biomarker for early breast cancer diagnosis, monitoring treatment response, and determining prognosis. In TNBC patients, ctDNA has an inherent tendency to characterize tumor heterogeneity and metastasis-specific mutations providing a key alternative to tumor tissue profiling. Several studies have already demonstrated the potential of ctDNA in TNBC patients from early to advanced stages of the disease including diagnosis, therapy decisions and assessment of prognosis. This review provides a critical brief summary of the evidence that gives credence to the utility of ctDNA as a biomarker for its role into clinical management in TNBC.

Citing Articles

Substrate stiffness modulates extracellular vesicles' release in a triple-negative breast cancer model.

Senigagliesi B, Geiss O, Valente S, Vondracek H, Cefarin N, Ceccone G Extracell Vesicles Circ Nucl Acids. 2024; 5(3):553-568.

PMID: 39697626 PMC: 11648499. DOI: 10.20517/evcna.2024.47.

Molecular Profiling of Endocrine Resistance in HR+/HER2-Metastatic Breast Cancer: Insights from Extracellular Vesicles-Derived DNA and ctDNA in Liquid Biopsies.

Martinez-Rodriguez A, Fuentes-Antras J, Lorca V, Lopez de Sa A, Perez-Segura P, Moreno F Int J Mol Sci. 2024; 25(23).

PMID: 39684756 PMC: 11641624. DOI: 10.3390/ijms252313045.

Monitoring response to neoadjuvant chemotherapy in triple negative breast cancer using circulating tumor DNA.

Chen J, Addanki S, Roy D, Bassett R, Kalashnikova E, Spickard E BMC Cancer. 2024; 24(1):1016.

PMID: 39148033 PMC: 11328413. DOI: 10.1186/s12885-024-12689-6.

Exploring Biomarkers in Breast Cancer: Hallmarks of Diagnosis, Treatment, and Follow-Up in Clinical Practice.

Lopez-Gonzalez L, Cendra A, Cendra C, Cervantes E, Espinosa J, Pekarek T Medicina (Kaunas). 2024; 60(1).

PMID: 38256428 PMC: 10819101. DOI: 10.3390/medicina60010168.

Roles of long noncoding RNA in triple-negative breast cancer.

Das P, Siddika A, Rashel K, Auwal A, Soha K, Rahman M Cancer Med. 2023; 12(20):20365-20379.

PMID: 37795578 PMC: 10652353. DOI: 10.1002/cam4.6600.

References

Jahr S, Hentze H, Englisch S, Hardt D, Fackelmayer F, Hesch R . DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res. 2001; 61(4):1659-65. View

Srinivasan M, Sedmak D, Jewell S . Effect of fixatives and tissue processing on the content and integrity of nucleic acids. Am J Pathol. 2002; 161(6):1961-71. PMC: 1850907. DOI: 10.1016/S0002-9440(10)64472-0. View

Gormally E, Hainaut P, Caboux E, Airoldi L, Autrup H, Malaveille C . Amount of DNA in plasma and cancer risk: a prospective study. Int J Cancer. 2004; 111(5):746-9. DOI: 10.1002/ijc.20327. View

Huang Z, Li L, Hua D . Quantitative analysis of plasma circulating DNA at diagnosis and during follow-up of breast cancer patients. Cancer Lett. 2006; 243(1):64-70. DOI: 10.1016/j.canlet.2005.11.027. View

Tampellini M, Berruti A, Bitossi R, Gorzegno G, Alabiso I, Bottini A . Prognostic significance of changes in CA 15-3 serum levels during chemotherapy in metastatic breast cancer patients. Breast Cancer Res Treat. 2006; 98(3):241-8. DOI: 10.1007/s10549-005-9155-y. View

Haffty B, Yang Q, Reiss M, Kearney T, Higgins S, Weidhaas J . Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol. 2006; 24(36):5652-7. DOI: 10.1200/JCO.2006.06.5664. View

Keir M, Butte M, Freeman G, Sharpe A . PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008; 26:677-704. PMC: 10637733. DOI: 10.1146/annurev.immunol.26.021607.090331. View

Liedtke C, Mazouni C, Hess K, Andre F, Tordai A, Mejia J . Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol. 2008; 26(8):1275-81. DOI: 10.1200/JCO.2007.14.4147. View

Frattini M, Gallino G, Signoroni S, Balestra D, Lusa L, Battaglia L . Quantitative and qualitative characterization of plasma DNA identifies primary and recurrent colorectal cancer. Cancer Lett. 2008; 263(2):170-81. DOI: 10.1016/j.canlet.2008.03.021. View

10.

Diehl F, Schmidt K, Choti M, Romans K, Goodman S, Li M . Circulating mutant DNA to assess tumor dynamics. Nat Med. 2008; 14(9):985-90. PMC: 2820391. DOI: 10.1038/nm.1789. View

11.

Dawood S, Broglio K, Kau S, Green M, Giordano S, Meric-Bernstam F . Triple receptor-negative breast cancer: the effect of race on response to primary systemic treatment and survival outcomes. J Clin Oncol. 2008; 27(2):220-6. PMC: 4516695. DOI: 10.1200/JCO.2008.17.9952. View

12.

Blows F, Driver K, Schmidt M, Broeks A, van Leeuwen F, Wesseling J . Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies. PLoS Med. 2010; 7(5):e1000279. PMC: 2876119. DOI: 10.1371/journal.pmed.1000279. View

13.

Duffy M, Evoy D, McDermott E . CA 15-3: uses and limitation as a biomarker for breast cancer. Clin Chim Acta. 2010; 411(23-24):1869-74. DOI: 10.1016/j.cca.2010.08.039. View

14.

Berrada N, Delaloge S, Andre F . Treatment of triple-negative metastatic breast cancer: toward individualized targeted treatments or chemosensitization?. Ann Oncol. 2010; 21 Suppl 7:vii30-5. DOI: 10.1093/annonc/mdq279. View

15.

Schwarzenbach H, Hoon D, Pantel K . Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer. 2011; 11(6):426-37. DOI: 10.1038/nrc3066. View

16.

Lehmann B, Bauer J, Chen X, Sanders M, Chakravarthy A, Shyr Y . Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011; 121(7):2750-67. PMC: 3127435. DOI: 10.1172/JCI45014. View

17.

Sharpe R, Pearson A, Herrera-Abreu M, Johnson D, Mackay A, Welti J . FGFR signaling promotes the growth of triple-negative and basal-like breast cancer cell lines both in vitro and in vivo. Clin Cancer Res. 2011; 17(16):5275-86. PMC: 3432447. DOI: 10.1158/1078-0432.CCR-10-2727. View

18.

Mouliere F, Robert B, Peyrotte E, Del Rio M, Ychou M, Molina F . High fragmentation characterizes tumour-derived circulating DNA. PLoS One. 2011; 6(9):e23418. PMC: 3167805. DOI: 10.1371/journal.pone.0023418. View

19.

Kim C, Tang G, Pogue-Geile K, Costantino J, Baehner F, Baker J . Estrogen receptor (ESR1) mRNA expression and benefit from tamoxifen in the treatment and prevention of estrogen receptor-positive breast cancer. J Clin Oncol. 2011; 29(31):4160-7. PMC: 3208536. DOI: 10.1200/JCO.2010.32.9615. View

20.

Nakai K, Mitomi H, Alkam Y, Arakawa A, Yao T, Tokuda E . Predictive value of MGMT, hMLH1, hMSH2 and BRCA1 protein expression for pathological complete response to neoadjuvant chemotherapy in basal-like breast cancer patients. Cancer Chemother Pharmacol. 2011; 69(4):923-30. DOI: 10.1007/s00280-011-1777-7. View